AquaBIT Molecular–Spatial Intelligence
From Blood to Body.
A Molecular Digital Twin.
AquaBIT integrates blood-derived molecular measurements with whole-body electrical phenotyping to explore where biological change may be expressed—and how it evolves over time.
Future research platform · Not currently approved for diagnosis or patient management
The central proposition
AquaBIT shows where change is occurring. Blood helps explain what may be occurring. AI connects them over time.
Genomics
Inherited architecture, susceptibility and pharmacogenomic context.
Molecular profiling
cfDNA, methylation, proteins, RNA and metabolites reflecting biological activity in blood.
AquaBIT
Multifrequency electrical measurements and reconstructed candidate tissue-property maps.
Blood biomarkers and multifrequency AquaBIT electrical measurements.
Computational reconstruction, regional features and longitudinal tissue characterisation.
Governed associations between molecular signatures and spatial electrical phenotypes.
Two views of the same patient
One patient. Two biological dimensions.
A spatial phenotype and a molecular phenotype remain distinct evidence streams—then meet inside a transparent computational model.
Spatial phenotype
Where biology becomes structure
AquaBIT measures electrical behaviour across frequencies to support reconstruction and longitudinal comparison.
Molecular phenotype
What processes may be active
The AquaBIT fusion engine
Two acquisition pathways.
One longitudinal model.
Blood-derived profile
AquaBIT examination
AI fusion engine
Molecular–Spatial Digital Twin
A continuously updateable representation linking measurement, reconstruction, inference and time.
The molecular layers
The digital twin is layered—not singular.
Each source answers a different biological question. AquaBIT does not directly measure these molecular layers; it integrates their blood-derived measurements with spatial electrical phenotyping.
Molecular diagnostic continuum
From current physiology to inherited biological context.
Blood-derived testing can describe progressively deeper layers of biology. Each layer answers a different question and remains an independent measurement stream.
Routine biomarkers
Haematology, biochemistry and inflammatory markers provide a clinically established view of current systemic physiology.
Measured in bloodProteome & metabolome
Proteins and metabolites characterise signalling, organ function, inflammation and the metabolic state present at sampling.
Measured molecular activitycfDNA & transcriptome
Cell-free DNA and circulating RNA can reveal tissue turnover, cellular injury and active biological pathways.
Blood-derived molecular signalEpigenome
Methylation and other regulatory patterns can add information about gene control and potentially tissue-associated origin.
Derived regulatory profileGenome
Validated genomic sequencing identifies inherited or acquired variants, disease susceptibility and potential pharmacogenomic treatment-response context.
Genetic measurementAquaBIT adds repeatable spatial electrical phenotyping. It does not establish a molecular or genetic diagnosis; validated laboratory assays and sequencing remain definitive. AI may test whether independently measured molecular signatures associate with regional electrical phenotypes over time.
A living model, not a static scan
What if disease could be recognised before anatomy significantly changes?
Repeated, radiation-free electrical measurements could be studied alongside molecular biomarkers over time—moving from isolated snapshots toward individual trajectories.
T0 · Baseline
Personal molecular and electrical reference state.
T1 · Molecular change
A blood-derived signature departs from baseline.
T2 · Tissue change
A regional electrical phenotype becomes detectable.
T3 · Clinical manifestation
Established imaging or pathology investigates the finding.
Clinical vision · Oncology
From molecular signal to targeted investigation.
AquaBIT is envisioned as a complementary longitudinal physiological imaging platform—not a replacement for pathology, genomic sequencing or established medical imaging.
Any clinically meaningful association would require prospective validation, defined intended use, regulatory review and comparison against established standards of care.
Blood testing
Identifies a validated abnormal pattern across circulating biomarkers, cfDNA or RNA, methylation, proteins, metabolites and—where clinically indicated—genomic variants.
AquaBIT examination
Measures a candidate regional change in electrical tissue characteristics.
Longitudinal AI comparison
Compares the finding with personal baseline and governed reference populations.
Definitive investigation
MRI, CT, PET, ultrasound or pathology is used where clinically appropriate.
Muscle, bone and rare disease
Following disease before it becomes irreversible.
Genetics can identify susceptibility; molecular biomarkers can indicate activity; AquaBIT could support repeated spatial monitoring of tissue change.
Molecular innovation roadmap
Build the evidence in layers.
Multimodal acquisition
Pair AquaBIT scans with blood multi-omics and established imaging under governed research protocols.
- Common data model
- Quality controls
- Personal baseline
Validated digital biomarkers
Test associations between electrical phenotypes, molecular signatures and confirmed clinical outcomes.
- Prospective cohorts
- External validation
- Bias and calibration review
Defined clinical pathways
Develop narrow intended uses for screening research, monitoring and treatment-response studies.
- Clinical utility
- Regulatory evidence
- Health-system integration
Named AquaBIT programme
The Human Electrical–Molecular Atlas
A long-term reference atlas connecting electrical tissue behaviour with molecular biology, anatomy, disease and outcomes across diverse populations.
Every paired examination strengthens a governed multimodal dataset that may support pattern recognition, disease stratification, longitudinal comparison and treatment-response research.
Personal baseline
You are your best control.
Population references matter, but each patient’s own history may reveal subtle departures that a single cross-sectional comparison cannot.
Research platform
Infrastructure for translational discovery.
AquaBIT can be explored as a research platform for paired electrical, imaging, molecular and outcome data.
Digital biomarkers
Study signatures that correlate electrical tissue features with genomic, proteomic or metabolic measures.
Response monitoring
Investigate repeatable phenotypes across therapy, recovery and disease progression.
Foundation datasets
Collaborate with universities, biobanks, cancer institutes, rare-disease centres and pharmaceutical programmes.
AquaBIT Molecular Intelligence
One blood sample.
One AquaBIT scan.
A new dimension of the human body.
Molecular biology should not be interpreted independently from anatomy. The future is a continuously evolving, evidence-aware spatial model of the patient.
